Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis

NCT ID: NCT01615887

Last Updated: 2022-09-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2011-08-31

Brief Summary

Amphetamines have been shown to improve cognition but its use is limited due to its side effects. Lisdexamfetamine is an amphetamine pro-drug, minimizing these effects and has been safely used in children and adults with Attention Deficit Hyperactivity Disorder (ADHD). The investigators hypothesize that lisdexamfetamine may improve cognitive abilities in MS patients with documented cognitive dysfunction. Because lisdexamfetamine is a stimulant its positive effects should be observed primarily in the domains of processing speed and working memory. The investigators therefore propose a study in which the primary objective will be to assess the efficacy of lisdexamfetamine in improving attention and processing speed in MS. The secondary objectives will be (a) the assessment of the safety and tolerability of lisdexamfetamine in the MS population, and (b) to test for effects of the drug on other cognitive domains, depression, and self and informant reports of cognitive and executive function demanding activities and behaviors.

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

lisdexamfetamine sulfate

30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks

Group Type: EXPERIMENTAL

lisdexamfetamine sulfate

Intervention Type: DRUG

30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks

Sugar pill

Placebo will be administered in the same fashion as the treatment arm

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

sugar pill

Interventions

lisdexamfetamine sulfate

30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks

Intervention Type: DRUG

placebo

sugar pill

Intervention Type: DRUG

Other Intervention Names

Vyvanse

Eligibility Criteria

Inclusion Criteria

• Males/Females who are ≥ 18 years old and < 55 years old and are capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education.
• Have a diagnosis of either Relapsing Remitting or Secondary Progressive MS, as per revised McDonald's Criteria (68).
• Have not received steroids in last thirty (30) days or a relapse in the last ninety (90) days, and whose MS is considered stable.
• Presence of cognitive dysfunction characterized by slowed processing speed as indicated by a score of -1.5 SD below age/education matched norms on the SDMT or the PASAT.
• An Expanded Disability Status Scale (EDSS) of ≤ 6.5
• Have given written informed consent prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care.
• Are capable of performing the requirements of a NP test battery including at least 20/70 near visual acuity by near vision chart, with correction allowed.
• If female, must neither be pregnant nor breast-feeding and must either (a) be > 12 months post-menopausal or surgically sterilized, or (b) agree to use an acceptable method of birth control for the duration of the study. Abstinence will not be considered an acceptable method of birth control.

Exclusion Criteria

• Have cognitive deficits caused by concomitant medication usage or other significant neurological/psychological disease e.g. Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack, Vascular Dementia, Huntington's disease, traumatic brain injury or chronic CNS infection
• Have evidence of other medical cause(s) of cognitive impairment
• Have evidence of major depression as determined by a positive BDIFS and clinician interview
• Have uncontrolled or labile hypertension, tachycardia, cardiovascular or cerebrovascular disease
• Have demonstrated a hypersensitivity to amphetamines in the past
• The following concomitant medications are not permitted to be used within 28 days of enrollment or during the study

• Monoamine Oxidase Inhibitors
• Inhaled Beta2-agonists
• Sympathomimetics
• Antipsychotic agents
• Modafinil
• Tricyclic Antidepressants
• Anticonvulsants other than gabapentin and pregabalin
• The following medications are permitted if the patient has been on a stable dose for ≥ 6 weeks:

• Short acting benzodiazepines, qhs administration only
• Gabapentin and pregabalin Cholinesterase inhibitors other than donepezil, galantamine, and rivastigmine
• Memantine
• Anti-spasmodics
• Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

State University of New York at Buffalo

OTHER

Sponsor Role: lead

Responsible Party

Bianca Weinstock-Guttman

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Kaleida Health, Jacobs Neurological Institute

Buffalo, New York, United States

Countries

United States

Other Identifiers

NEU2570309B

Identifier Type: -

Identifier Source: org_study_id